Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024.
2024年8月1日維州阿什本(GLOBE NEWSWIRE)-- Quoin Pharmaceuticals Ltd.(納斯達克:QNRX)(以下簡稱"公司"或"Quoin"),一家專注於罕見和孤兒病的臨床專業藥品公司,今天宣佈該公司計劃於2024年8月8日星期四市場開盤前發佈2024年第二季度財務業績報告。
The announcement will provide an operational update regarding the company's achievements during the quarter and will detail financial highlights.
該公告將提供有關公司在該季度取得成就的運營更新,並詳細說明財務亮點。
About Quoin Pharmaceuticals Ltd.
關於Quoin Pharmaceuticals Ltd.公司:Quoin Pharmaceuticals Ltd.是一家專注於開發和商業化治療罕見和孤兒疾病的治療產品的臨床專業藥品公司。我們致力於滿足患者、家庭、社區和護理團隊的未滿足的醫療需求。Quoin的創新管道包括四種正在研發的產品,具有共同的潛力,以針對廣泛的罕見和孤兒適應症,包括內瑟頓綜合徵、剝脫性皮膚綜合徵、掌蹠角化症、硬皮病、表皮鬆解性水皰病和其他疾病。欲獲取更多信息,請訪問:Quoin Pharmaceuticals Ltd.網站或LinkedIn更新。
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: or LinkedIn for updates.
公司提醒,本新聞稿中不是歷史事實描述的陳述均屬於根據1995年《私人證券訴訟改革法》的前瞻性陳述。前瞻性陳述可能通過使用涉及未來事件或情況的詞語,如"預期"、"意圖"、"計劃"、"預測"、"相信"和"將"等等進行識別。除了歷史事實的陳述外,反映公司對未來的期望、假設、投影、信念或意見的所有陳述均爲前瞻性陳述。因爲這些陳述存在風險和不確定性,實際結果可能與這些前瞻性陳述所表達的結果存在實質性的差異。這些前瞻性陳述基於公司目前的預期並涉及可能永遠無法實現或可能被證明不正確的假設。實際結果和事件的時間可能與這些前瞻性陳述所預期的結果和事件的時間存在實質性的差異。有關可能導致實際結果與本新聞稿中所包含信息不符的因素的更多信息,請參閱該公司提交給SEC的截至2023年12月31日的10-K表和該公司隨後提交給SEC的表格10-Q和8-K。該公司不承擔更新這些陳述以反映其所做陳述之後發生的事件或存在的情況的義務,但法律可能要求該公司這樣做。
Cautionary Note Regarding Forward Looking Statements
關於前瞻性聲明的警告
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. For additional information concerning factors that could cause actual results to differ materially from the information contained in this press release, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2023 that the Company filed with the SEC and the Company's subsequent filings with the SEC on Forms 10-Q and 8-K. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
公司注意到,本新聞稿中非歷史事實描述的陳述屬於《1995年《私人證券訴訟改革法》》規定的前瞻性陳述。前瞻性陳述可能是使用涉及未來事件或情況的詞語,如「預計」,「打算」,「計劃」,「預測」,「相信」和「將要」等。除歷史事實陳述外,反映公司對未來的期望,假設,投射,信念或意見的所有陳述,均屬於前瞻性陳述。由於這些陳述存在風險和不確定性,實際結果可能與此類前瞻性陳述所表達或暗示的結果有所不同。這些前瞻性陳述基於公司當前的期望,並涉及可能永遠無法實現或可能被證明不正確的假設。實際結果和事件的時間可能與此類前瞻性陳述所預計的有所不同。有關可能導致實際結果與本新聞稿所包含信息有所不同的因素的附加信息,請查閱公司在2023年12月31日結束的10-K表格和公司在SEC提交的之後關於10-Q和8-K表格的提交。除法律另有規定外,公司無義務更新此類陳述以反映發生或存在於其發佈之後的事件或情況。
For further information, contact:
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
如需更多信息,請聯繫:
投資者關係
PCG 諮詢
傑夫·拉姆森
jramson@pcgadvisory.com
(646) 863-6341